What is the efficacy of second line therapy for metastatic bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Previously, second-line therapy had represented a significant unmet medical need. While vinflunine, a vinca alkaloid, was approved in Europe based on the results of a phase III trial versus best supportive care in the second-line setting, its efficacy is marginal. [133] The median survival for patients treated with second-line therapy such as vinflunine or other agents, including the taxanes and pemetrexed, is only 6-9 months.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!